Join the Oncology Voice Network. Join for Free
The Augmented MSL
artificial intelligence in healthcare Pfizer MSL life AI tools in medical field generative AI tools AI in women's health

The Augmented MSL


Share This Article


Summary

This week's guest is Nandini Sabharwal, Director, Migraine and Women's Health, Field Medical Group at Pfizer and we discuss the role of artificial intelligence in every day MSL life.

Key Points

  • Embracing AI can significantly reduce preparation time for MSLs by providing quick, insightful answers and aiding in role-specific tasks such as healthcare provider meeting prep and advisory board planning.
  • Effective use of generative AI tools like ChatGPT or Microsoft Copilot requires learning how to craft detailed, specific prompts and understanding the limitations of these tools, including the necessity of refining the output manually.
  • Company buy-in and licensing are crucial for integrating AI tools into daily workflows, and while the initial learning curve can be steep, the productivity gains and potential for improved communication make it a worthwhile investment for MSLs.

Click for Source
artificial intelligence in healthcare, Pfizer MSL life, AI tools in medical field, generative AI tools, AI in women's health

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN